Partial
Needs Revision
Patient Risk:
Moderate
Summary
Some hepatotoxicity-alcohol risk statements are supported by the label (increased risk with heavy alcohol; monitoring liver tests; hepatic impairment increases risk), but many counseling-style recommendations and specific symptom/urgency and reporting examples are not supported by the provided prescribing information excerpts.
Category Scores
Accurate Statements
Drinking alcohol while taking methotrexate can raise the risk of liver injury.
Label 5.5: 'The risk of hepatotoxicity is increased with heavy alcohol consumption.'
Alcohol and methotrexate are both associated with liver injury risk (hepatotoxicity).
Label 5.5: TREXALL can cause hepatotoxicity and risk is increased with heavy alcohol consumption.
The risk of hepatotoxicity increases with total cumulative dose of methotrexate.
Label 5.5: 'risk of hepatotoxicity appears to increase with total cumulative dose' and cumulative-dose threshold described.
Patients with hepatic impairment may be at increased risk and should be closely monitored; dosage reduction/discontinuation may be appropriate.
Label 8.7: 'Patients with hepatic impairment may be at increased risk...' and 'Closely monitor... Reduce the dosage or discontinue... as appropriate.'
Unsupported Statements
Many clinicians advise avoiding alcohol or keeping alcohol very limited while taking methotrexate.
No label text in provided excerpts attributes specific clinician advice or an avoid/limit directive.
There is no universal safe amount of alcohol for patients taking methotrexate.
Label only states increased risk with heavy alcohol consumption; it does not state 'no universal safe amount.'
The safest approach for alcohol use while taking methotrexate is to avoid alcohol unless the prescriber specifically says it is okay.
Label does not give a directive to avoid alcohol absent prescriber approval; it only addresses increased risk with heavy alcohol consumption.
Higher methotrexate doses generally carry more risk than lower weekly doses used for rheumatoid arthritis and psoriasis.
Provided label excerpt links hepatotoxicity risk to total cumulative dose, but does not compare dosing across RA/psoriasis vs other dosing or make this RA/psoriasis-specific comparison.
If a patient already drank once or a small amount before realizing there were alcohol restrictions, it usually does not automatically mean severe harm.
No label guidance on one-time/small intake reassurance or severity after accidental consumption.
If a patient drank alcohol before realizing restrictions, they should contact their prescriber for guidance.
Provided patient counseling excerpt advises informing providers of concomitant medications and reporting hepatic toxicity signs/symptoms, but does not provide alcohol-specific 'contact prescriber' instruction.
A patient should tell the prescriber how much they drank and when.
No label text in provided excerpts instructs patients to report alcohol quantity/timing to the prescriber.
Patients should contact their clinician urgently if they develop signs of liver problems such as dark urine.
Provided excerpts do not mention dark urine as a hepatic toxicity sign or specify urgency for hepatic symptoms beyond 'report signs or symptoms.'
Patients should contact their clinician urgently if they develop signs of liver problems such as severe fatigue.
Severe fatigue is not mentioned as a hepatic toxicity sign in the provided excerpts.
Patients should contact their clinician urgently if they develop signs of liver problems such as persistent nausea or vomiting.
Persistent nausea/vomiting are not explicitly framed as signs of hepatic toxicity in the provided counseling excerpts (GI toxicity counseling is present but hepatic-specific framing is not).
Patients should contact their clinician urgently if they develop signs of liver problems such as right upper abdominal pain.
Right upper abdominal pain is not mentioned in the provided hepatic toxicity counseling excerpt.
The response suggests asking about the methotrexate dose and schedule (weekly dose vs other regimen).
No provided label excerpt includes alcohol-interaction counseling that suggests asking about dose/schedule.
The response suggests discussing alcohol intake with the prescriber, including how much.
No provided label excerpt advises discussing alcohol intake with the prescriber or quantifying it.
The response suggests discussing any history of liver disease or hepatitis with the prescriber.
Although hepatic impairment monitoring is described (8.7), the provided patient counseling excerpt does not instruct patients to discuss liver disease/hepatitis history specifically.
The response suggests reviewing recent liver blood test results (AST/ALT).
Label 5.5 says to monitor liver tests but the provided excerpts do not specify AST/ALT or frame this as patient 'review recent results' counseling.
Contradictions
Important Omissions
Label does not support patient-specific 'urgent' escalation or detailed hepatic symptom examples (e.g., dark urine, severe fatigue, RUQ pain) as written; the response omits aligning to the label’s general instruction to report signs/symptoms of hepatic toxicity and to monitor liver tests.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While the core risk relationship (heavy alcohol increases hepatotoxicity risk) is label-supported, multiple specific counseling statements (avoid unless prescriber ok; one-time reassurance; detailed symptom/urgency triggers; reporting alcohol quantity/timing; alcohol-specific provider contact) are not supported by the provided prescribing information, which may lead to miscalibrated patient actions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Revision
Primary Issue
Numerous alcohol-counseling and symptom/urgency/amount-reporting instructions are not supported by the provided label excerpts; label-supported content should be restated more generally (e.g., increased risk with heavy alcohol; monitor liver tests; report signs/symptoms of hepatic toxicity).
Suggested Improvement
Restrict claims to label-supported statements in 5.5 (hepatotoxicity risk increased with heavy alcohol consumption; risk increases with total cumulative dose; monitoring liver tests at baseline and periodically) and 8.7 (hepatic impairment increased risk; closely monitor; reduce/discontinue as appropriate). For patient counseling, use label wording 'report signs or symptoms of hepatic toxicity' without adding unsupported specific symptom examples or 'urgent' directives unless present in the provided label text.